Harnessing the Power of Radiopharmaceuticals

Engineered molecules

Our bespoke, iterative approach to radiotherapeutic design is fueled by a toolbox of technologies for peptide-based radiopharmaceuticals.

Learn Our Approach

Our pipeline

We are developing a robust pipeline of radiopharmaceuticals to address targets spanning solid and hematologic malignancies.

View Our Pipeline

Industry-leading team

Backed by top-tier investors, our team has decades of expertise developing radiopharmaceuticals for highly targeted treatment of cancer.

Meet the Team

News & Events

March 7, 2023

Alpha-9 Theranostics Strengthens its Scientific Expertise with Key Appointments to Leadership Team and Scientific Advisory Board

Dr. Jutta Wanner to lead R&D discovery efforts and support the continued expansion of Alpha-9’s differentiated radiopharmaceutical pipeline Dr. Jason Lewis and...

December 14, 2022

Alpha-9 Theranostics Announces Oversubscribed $75 Million Series B Financing to Advance Portfolio of Radiopharmaceuticals for Cancer

Company is developing bespoke radiopharmaceuticals with capital efficient and rapid approach Proceeds to support progression of five candidates into the clinic, expansion...

October 13, 2022

Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement

BOSTON, Mass. and VANCOUVER, British Columbia, October 13, 2022 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Alpha-9 Theranostics Inc. (Alpha-9), a...